Low-Dose Aspirin for Cardiovascular Prevention in Giant Cell Arteritis—Time to Reconsider?
By
Guillaume Marquis-Gravel
Jean-Paul Makhzoum
April 17, 2026
Clinical Scorecard: Reevaluating the Role of Low-Dose Aspirin in Preventing Cardiovascular Events in Giant Cell Arteritis
At a Glance
Category Detail
Condition Giant Cell Arteritis (GCA) Key Mechanisms Vascular inflammation and potential ischemic benefits versus bleeding risks. Target Population Patients with incident GCA, particularly older individuals with comorbidities. Care Setting Hospital discharge following first hospitalization for GCA.
Key Highlights
Low-dose aspirin may reduce major adverse cardiovascular events (MACE) at 1 year. Increased risk of major hemorrhage associated with low-dose aspirin. Net clinical benefits of low-dose aspirin in GCA remain neutral at 1 and 3 years. Current guidelines discourage routine aspirin use for primary cardiovascular prevention in GCA. Shared decision-making is essential considering patients' preferences regarding risks. Guideline-Based Recommendations
Diagnosis
GCA is a medical emergency requiring rapid intervention. Management
Low-dose aspirin is not routinely recommended for primary cardiovascular prevention in GCA. Monitoring & Follow-up
Monitor for ischemic events and bleeding risks in patients prescribed low-dose aspirin. Risks
Increased risk of major hemorrhage with low-dose aspirin use. Patient & Prescribing Data
Patients with a first hospitalization for GCA, naive to chronic antithrombotic therapy.
Low-dose aspirin showed a relative risk reduction in MACE but also increased bleeding risk.
Clinical Best Practices
Consider individual patient risk factors and preferences in treatment decisions. Utilize shared decision-making to discuss the risks and benefits of low-dose aspirin. References
